PL1868623T3 - Zastosowanie LGG w wytwarzaniu leku do zapobiegania lub leczenia alergii oddechowych - Google Patents

Zastosowanie LGG w wytwarzaniu leku do zapobiegania lub leczenia alergii oddechowych

Info

Publication number
PL1868623T3
PL1868623T3 PL06739278T PL06739278T PL1868623T3 PL 1868623 T3 PL1868623 T3 PL 1868623T3 PL 06739278 T PL06739278 T PL 06739278T PL 06739278 T PL06739278 T PL 06739278T PL 1868623 T3 PL1868623 T3 PL 1868623T3
Authority
PL
Poland
Prior art keywords
lgg
medicament
prevention
manufacture
treatment
Prior art date
Application number
PL06739278T
Other languages
English (en)
Inventor
Udo Herz
Harald Renz
Nicole Bluemer
Holger Garn
Original Assignee
Mjn U.S. Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36698734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1868623(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/106,792 external-priority patent/US20060233772A1/en
Application filed by Mjn U.S. Holdings Llc filed Critical Mjn U.S. Holdings Llc
Publication of PL1868623T3 publication Critical patent/PL1868623T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PL06739278T 2005-04-15 2006-03-22 Zastosowanie LGG w wytwarzaniu leku do zapobiegania lub leczenia alergii oddechowych PL1868623T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/106,792 US20060233772A1 (en) 2005-04-15 2005-04-15 Method for preventing or treating the development of respiratory allergies
US11/144,287 US7303745B2 (en) 2005-04-15 2005-06-03 Method for preventing or treating the development of respiratory allergies

Publications (1)

Publication Number Publication Date
PL1868623T3 true PL1868623T3 (pl) 2017-03-31

Family

ID=36698734

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06739278T PL1868623T3 (pl) 2005-04-15 2006-03-22 Zastosowanie LGG w wytwarzaniu leku do zapobiegania lub leczenia alergii oddechowych

Country Status (14)

Country Link
US (6) US7303745B2 (pl)
EP (1) EP1868623B1 (pl)
KR (2) KR101277447B1 (pl)
CN (1) CN105832774B (pl)
BR (1) BRPI0609077A2 (pl)
CA (3) CA2991508C (pl)
ES (1) ES2599156T3 (pl)
MX (1) MX2007012538A (pl)
MY (2) MY147175A (pl)
NO (1) NO20073900L (pl)
PL (1) PL1868623T3 (pl)
RU (1) RU2435598C2 (pl)
TW (1) TWI369210B (pl)
WO (1) WO2006113035A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7862808B2 (en) * 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US8075934B2 (en) * 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
CA2645472C (en) * 2006-03-10 2015-09-15 N.V. Nutricia Use of non-digestable saccharides for giving an infant the best start after birth
WO2008064489A1 (en) * 2006-12-01 2008-06-05 Mcmaster University Probiotics to inhibit inflammation
EP1974734A1 (en) † 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity
MX2010005132A (es) * 2007-11-08 2010-06-02 Nestec Sa Uso de oligosacaridos conteniendo n-acetilactosamina para maduración de las respuestas inmunes en neonatos.
US9483911B2 (en) 2008-04-30 2016-11-01 Bally Gaming, Inc. Information distribution in gaming networks
WO2009151315A1 (en) * 2008-06-13 2009-12-17 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
SI2285387T1 (sl) 2008-06-13 2016-02-29 N.V. Nutricia Prehrana za preprečevanje infekcij
WO2010002241A1 (en) * 2008-06-30 2010-01-07 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
WO2010071421A1 (en) * 2008-12-17 2010-06-24 N.V. Nutricia Probiotics for the treatment and/or prevention of pulmonary hypertension
EP2295535A1 (en) * 2009-09-11 2011-03-16 Mead Johnson Nutrition Company Probiotic material
JP4942831B2 (ja) * 2010-03-19 2012-05-30 株式会社キティー 抗アレルギー用組成物
WO2013187755A1 (en) 2012-06-14 2013-12-19 N.V. Nutricia Fermented infant formula with non digestible oligosaccharides
EP3079502A1 (en) 2013-11-04 2016-10-19 N.V. Nutricia Fermented formula with non digestible oligosaccharides
WO2019169258A1 (en) * 2018-03-01 2019-09-06 The Regents Of The University Of California Methods and compositions relating to epoxide hydrolase genes

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
US5840318A (en) * 1993-05-11 1998-11-24 Immunom Technologies, Inc. Methods and compositions for modulating immune systems of animals
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
JPH092959A (ja) 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
EP1039892B1 (en) 1997-02-21 2004-04-28 Abbott Laboratories Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
HUP0104760A2 (hu) 1998-12-15 2002-04-29 American Home Products Corporation Eljárás és készítmény a bél épségének megtartására és helyreállítására
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
AU4905300A (en) * 1999-05-25 2000-12-12 Andrew W. Bruce Oral administration of lactobacillus for the maintenance of health in women
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
FI113741B (fi) 1999-11-01 2004-06-15 Valio Oy Menetelmä verenpainetta alentavia peptidejä sisältävän tuotteen valmistamiseksi
AU2001233529A1 (en) * 2000-02-10 2001-08-20 Andrew W. Bruce Probiotic therapy for newborns
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
CN1444484A (zh) * 2000-06-19 2003-09-24 穆科普罗泰科有限公司 用益生菌对粘膜表面的细菌或病毒感染进行治疗或免疫治疗及用于此的组合物
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
WO2002062360A1 (en) * 2001-02-06 2002-08-15 Societe Des Produits Nestle S.A. Endotoxin binding by lactic acid bacteria and bifidobacteria
US20040067965A1 (en) * 2001-02-16 2004-04-08 Balogh Douglas Wayne Antiviral method of use
EP1239032A1 (en) 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP3853673B2 (ja) 2001-03-09 2006-12-06 森永乳業株式会社 Ｃ型慢性肝炎治療剤
EP1243273A1 (en) * 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
EP1260227A1 (en) * 2001-05-23 2002-11-27 Societe Des Produits Nestle S.A. Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
ES2192151B1 (es) * 2002-03-15 2005-02-01 Universidad Politecnica De Valencia Linea de retardo multiple basada en awg y diferentes tramos de un medio optico dispersivo.
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
AU2002951270A0 (en) * 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
ATE513551T1 (de) * 2003-01-24 2011-07-15 Flora Technology Inc Zusammensetzungen und verfahren zur wiederherstellung der bakterienflora
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies

Also Published As

Publication number Publication date
CA2991508A1 (en) 2006-10-26
MX2007012538A (es) 2007-12-10
US7867485B2 (en) 2011-01-11
NO20073900L (no) 2008-01-10
CN105832774B (zh) 2020-03-06
US20080085267A1 (en) 2008-04-10
CA2604846A1 (en) 2006-10-26
KR20130058767A (ko) 2013-06-04
US20060233773A1 (en) 2006-10-19
US20080118485A1 (en) 2008-05-22
TW200716145A (en) 2007-05-01
US20080131413A1 (en) 2008-06-05
RU2435598C2 (ru) 2011-12-10
EP1868623A1 (en) 2007-12-26
EP1868623B1 (en) 2016-08-31
MY147175A (en) 2012-11-14
US20080118484A1 (en) 2008-05-22
CA2881536A1 (en) 2006-10-26
BRPI0609077A2 (pt) 2010-02-17
TWI369210B (en) 2012-08-01
CN105832774A (zh) 2016-08-10
CA2881536C (en) 2018-02-13
RU2007137994A (ru) 2009-05-20
CA2991508C (en) 2019-06-25
ES2599156T3 (es) 2017-01-31
WO2006113035A1 (en) 2006-10-26
MY162223A (en) 2017-05-31
CA2604846C (en) 2015-05-05
KR20070122479A (ko) 2007-12-31
US7837989B2 (en) 2010-11-23
US7303745B2 (en) 2007-12-04
KR101277447B1 (ko) 2013-06-28
US7867486B2 (en) 2011-01-11
US20080118483A1 (en) 2008-05-22
US7923006B2 (en) 2011-04-12

Similar Documents

Publication Publication Date Title
TWI369210B (en) Use of lgg in the manufacture of a medicament for the prevention or treatment of respiratory allergies
IL210589A (en) C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB
IL183101A (en) Use of tetrahydrocannabivarin in drug production
IL186662A (en) Use of bis (thiohydrazide amide) to prepare a drug for the treatment of human cancer
EP1701756A4 (en) MACRO CONTROL OF THE TREATMENT OF BREATHING IN SLEEP
ZA200802897B (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease
IL190284A (en) Use of milenzipran, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia
IL173060A0 (en) Medical product expiration alerting
IL200278A (en) Use of aclidinium for the manufacture of a drug for use in the treatment or prevention of respiratory illness and pharmacist's preparation for the treatment or prevention of respiratory illness
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
GB0410399D0 (en) The treatment of respiratory disease
IL178815A0 (en) The treatment of respiratory disease
IL185444A0 (en) Novel drugs for treating respiratory diseases
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
IL177609A (en) Use of gobacoline or its analogue to produce a drug to treat liver carcinoma
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
IL198493A0 (en) Use of epothilones in the treatment of osteoporosis and related diseases
GB0415181D0 (en) Compounds for use in the treatment of infection
PL1714647T3 (pl) Zastosowanie agomelatyny do wytwarzania leku do leczenia zaburzeń dwubiegunowych
PL1656949T3 (pl) Zastosowanie alfa-1 antytrypsyny do wytwarzania leków do leczenia fibromialgii
IL191208A (en) Use of phenofibrate or its derivative for the preparation of a drug for the treatment of diabetic retinopathy
IL185691A0 (en) Novel compounds derived from 5-thioxylose and therapeutic use thereof
IL198290A0 (en) Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies
EP1864671A4 (en) USE OF HYDROCHLORIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HYPERTENSION
ZA200900556B (en) Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders